Zenotech Laboratories Ltd Stock Analysis

BSE: 532039 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 29-Nov-2022 18:01
64.50 5.60 (9.51%)

DeciZen - Make an Informed Decision on Zenotech Laboratorie

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Zenotech Laboratorie Price Chart

P/E Ratio (SA) :
14.81
Market Cap :
359.5 Cr.
52-wk low :
40
52-wk high :
74.8
Bole Toh?

1. Is Zenotech Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Zenotech Laboratories Ltd is a below average quality company.

2. Is Zenotech Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Zenotech Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Zenotech Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Zenotech Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zenotech Laboratorie:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zenotech Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % -48.9%-41.8%-66.4%-77.1%932.9%-66.7%-5.9%10.9%-0.2%31.6%-
Value Creation Index -4.5-4.0NANANA-5.8-1.4-0.2-1.01.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 32.84.12.12.311.1132622.536.637
YoY Gr. Rt. %--9.2%47.8%-49.5%9.2%395.1%17%99.7%-13.7%62.9%-
Adj EPS -7-6.2-8.4-5.2-5.8-1.9-0.51-0.23.64
YoY Gr. Rt. %-NANANANANANANA-119.2%NA-
BVPS (₹) 7.20.9-7.5-12.7-18.26.96.48.17.911.612.7
Adj Net Profit -25.3-22.6-30.3-18.9-21.1-11.8-36.3-1.222.224
Cash Flow from Ops. -9.8-24.3-7.7-4.81.6-16.3-1411.45.717.7-
Debt/CF from Ops. -1.7-1.9-7-11.333.20-1.41.63.60.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 31.8%74.7%41.1%62.9%
Adj EPS NANANANA
BVPS 5.402245.9
Share Price 7.5% 3.4% 35.1% 50%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -65-154252.851.637.799.2-7.514.3-2.537.332.9
Op. Profit Mgn % -667.6-617-488.2-372.5-460.4-70.5-2634.528.447.856
Net Profit Mgn % -830.2-820.9-743.6-917.4-937.4-106.3-23.324.3-5.460.765.2
Debt to Equity 0.614.4-2-1.2-0.800.50.40.40.10
Working Cap Days 66783254384261014823912511176123
Cash Conv. Cycle 89297186252106-70-42-44-990

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 32.90%

Sales growth is growing at healthy rate in last 3 years 41.06%

Sales growth is good in last 4 quarters at 42.27%

No data to display

Latest Financials - Zenotech Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 4 -2.1
TTM Sales (₹ Cr.) 37.3 6.6
BVPS (₹.) 12.7 0
Reserves (₹ Cr.) 16 62
P/BV 4.66 0.00
PE 14.81 0.00
From the Market
52 Week Low / High (₹) 40.00 / 74.75
All Time Low / High (₹) 3.99 / 173.59
Market Cap (₹ Cr.) 359
Equity (₹ Cr.) 61
Face Value (₹) 10
Industry PE 37.4

Management X-Ray of Zenotech Laboratorie :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zenotech Laboratorie

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Zenotech Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zenotech Laboratorie on 29-Nov-2022 18:01 is : 64.50.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Nov-2022 18:01 the market cap of Zenotech Laboratorie stood at ₹ 359.5.
The latest PE ratio of Zenotech Laboratorie as of 29-Nov-2022 18:01 is 14.81.
The latest PB ratio of Zenotech Laboratorie as of 29-Nov-2022 18:01 is 4.66
The 52-week high of Zenotech Laboratorie is ₹ 74.75 and the 52-week low is ₹ 40.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Zenotech Laboratorie is ₹ 37.28 ( Cr.) .

About Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.

Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.

Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.

Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.

Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.

Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.

Product range of the company includes:

Generics -- Biological

  • Nugraf
  • Macrogen

        Chemical

  • Gemcitabine for Injection 
  • Paclitaxel for Injection 
  • Docetaxel for Injection 
  • Irinotecan for Injection 
  • Oxaliplatin for Injection 
  • Epirubicin for Injection 
  • Bleomycin for Injection 
  • Cisplatin for Injection 
  • Carboplatin for Injection 
  • Ifosfamide for Injection 
  • Etoposide for Injection

New biologicals Zenotech develops new biological entities in the areas of

  • Cancer
  • Neurology
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now